This site uses cookies. By using this site you agree to receiving cookies. View Policy.

160%

Rescape is pioneering the use of VR to solve challenges in healthcare and frontline services. Their DR.VR platform launched in 2019 can help patients reduce pain and anxiety in hospitals and care homes. Their proprietary content and modular platform has already been sold to NHS hospitals and to Serco.

  • AR/VR healthcare market to hit $30.40bn by 2026 with a CAGR of 42.4%
  • Studies have shown positive results of DR.VR helping pain and anxiety
  • COVID-19 creating multiple opportunities to help healthcare systems
  • Directors have previously founded and exited £multimillion businesses

Idea

Rescape - join our journey!
Dr Ceri Lynch, Consultant Anaesthetics NHS
Dr Ceri Lynch, Consultant Anaesthetics NHS
Dr Roisin Begley, Paediatric Emergency Medicine Consultant NHS
Dr Roisin Begley, Paediatric Emergency Medicine Consultant NHS
Study published in May 2020 been published in ICU by Management Dr Ceri Lynch
Study published in May 2020 been published in ICU by Management Dr Ceri Lynch
Accident prone paediatrics patient with a unique take on how VR helps!
Accident prone paediatrics patient with a unique take on how VR helps!
ICU Patient, Cwm Taff Morgannwg UHB
ICU Patient, Cwm Taff Morgannwg UHB
Lindsay Abraham, Hospital Director and Registered Manager at Krinvest Care Group
Lindsay Abraham, Hospital Director and Registered Manager at Krinvest Care Group
DR.VR content
DR.VR content
DR.VR content
DR.VR content
DR.VR content
DR.VR content
Data collected is uploaded to the DR.VR portal anonymously
Data collected is uploaded to the DR.VR portal anonymously

Imagine a world where hospitals can reduce their patients' pain & anxiety with less reliance on drugs. Where blue light workers not only learn empathy but feel it and develop strategies not only to cope but thrive. Rescape is building the VR content & platform that can help support this, using our shareable, single- & multi-user VR headset solutions.

The AR/VR in Healthcare Market is predicted to reach USD 30-40bn by 2026.

In 2019 we launched and validated DR.VR, selling a yearly licence directly to innovators in hospitals, hospices, care homes & trained prison custody officers for SERCO.

In 2021, our vision is to turn these healthcare innovators into early adopters. Evidence is key & 2 studies have already shown positive results for DR.VR. Now, collaborating with the Centre for Trials Research, Cardiff University we launched www.futureVISION.health.

In a new COVID-19 world, we believe that Rescape is well set to solve new healthcare challenges. By 2021 we aim to address infection control, explore grants, faster research & new product opportunities incl refining the platform & further research biofeedback with the AI opportunities it brings.

As an industry, there are over 20 years of clinical research with 1000's of studies showing the opportunities for healthcare. Rescape is building on this body of work and believe we are well placed to be at the centre of it in the UK & globally.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Rescape pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered?
Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Rescape has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.